Offering consensus guidance on when and how to screen for thalassemia and sickle cell disease carriers, including clear communication that respects cultural context and supports informed reproductive choices. See how the authors frame these recommendations here 👉https://bit.ly/4fO3Xp0

p53 in normal blood formation + MPNs. Dr Charles de Bock talks with Dr Isabelle Plo & Dr Barbara Monte-Mór on TP53 mutations, leukemic transformation, and emerging p53‑targeted therapies. Listen: https://bit.ly/4tq6QQ2 Review: https://bit.ly/4sZbo01

Authors of this paper offer reassuring real-world evidence for clinicians treating lymphoma patients with prior #HBV exposure, showing that, with antiviral prophylaxis, occult HBV infection should not preclude anti-CD19 #CAR-T therapy. https://bit.ly/4tTOoQ2

This paper shows poor survival after relapse following second-line #CAR T-cell therapy in large B-cell lymphoma #LBCL. The authors highlight the need for new strategies and dedicated trials. Read more 👉https://bit.ly/42SwX7j

New Episode! Host Dr Charles de Bock delves into ground-breaking preclinical research exploring the potential of tasquinimod to restore blood cell production and modify the bone marrow microenvironment in #MDS with Dr Manja Wobus and Dr Katja Sockel 🎧 https://hsphere.pub/wom

This paper reviews emerging in vivo #CAR therapies, outlining delivery platforms, clinical progress, and key challenges. The authors highlight how these approaches could help overcome manufacturing and access barriers in cell therapy. Read in depth 🔎https://bit.ly/4d1mfjP

At #EHA2026, we were honored to issue our final #HemaSphereAwards to our top 2025 peer-reviewer, Austin Kulasekararaj. We are grateful for Austin's outstanding peer-review contributions and for supporting the hematology publication landscape. 🙌

At #EHA2026, the #HemaSphereAwards recognize authors of influential heme publications. Congrats to Maximilian Merz, Nico Gagelmann, & coauthors for their highly cited (WoS) paper on idec-cel or cilta-cel for #RRMM 👉https://onlinelibrary.wiley.com/doi/10.1002/hem3.70070 @nicogagelmann.bsky.social

This paper identifies IGH::BCL3-positive #CLL as a distinct biological subtype with shared genetic and epigenetic features. Authors also suggest venetoclax may help overcome poor outcomes seen with chemoimmunotherapy.  Read about it here 👉https://bit.ly/4unom8F

At #EHA2026, the #HemaSphereAwards recognize authors of influential heme publications. Congratulations to Achille Iolascon, Ali Taher, & coauthors for their guidelines publication on diagnosis, tx, & prevention of iron deficiency + anemia👉https://onlinelibrary.wiley.com/doi/10.1002/hem3.108

At #EHA2026, the #HemaSphereAwards recognize authors of influential hematology publications. Congratulations to Ana Luísa Pereira, Serena Galli, and César Nombela-Arrieta for their study on bone marrow niches for hematopoietic stem cells👉https://onlinelibrary.wiley.com/doi/10.1002/hem3.133

At #EHA2026, the #HemaSphereAwards recognize authors of influential hematology publications. Congrats to Evgenii Shumilov, Georg Lenz, & coauthors for their study on CAR-T efficacy & toxicity in pts with DLBCL aged 70+ compared to younger pts👉https://onlinelibrary.wiley.com/doi/10.1002/hem3.54

Are you at #EHA2026 and need a break? Find our nook by the amazing poster area. Have a seat, charge your phone, chat with colleagues.

This Perspective outlines major gaps in #AYA hematology care across Europe. The authors call for shared standards, better transition support, and stronger research to improve outcomes.  Read more from the authors here:  https://bit.ly/42LFKYX @EHA_Hematology

At #EHA2026, the #HemaSphereAwards recognize authors of highly influential heme papers. Congrats to Syed A Mian, Linda Ariza-McNaughton, & coauthors for their study on donor-recipient sex influence on engraftment of normal + leukemia stem cells👉https://onlinelibrary.wiley.com/doi/10.1002/hem3.80

Interested in scientific publishing? Looking to learn more about the role of a peer reviewer, and how to enhance your own papers for reviewers? Come to the HemaSphere Peer Review Workshop at #EHA2026, starting soon! 📍13:45 - 15:15, Stockholm convention room T3 🎤Hosts: Jan Cools + Juerg Schwaller

🚨Today at 13:45 in Room T3: HemaSphere Peer Review Workshop, hosted by Jan Cools and Juerg Schwaller. Learn more about serving as a peer reviewer in scientific journals. As well, gain intel on how to make your own manuscripts shine their brightest for peer reviewers. All are welcome! #EHA2026

At #EHA2026, we were thrilled to award Michael Tomasson & coauthors with the HemaSphere Top-Cited Publication Award 2026 during the Opening Ceremony. Read more about their updates on long-term survival + safety of elranatamab in pts with R/R MM👉https://onlinelibrary.wiley.com/doi/10.1002/hem3.136

Prof Claire Harrison received EHA's Lifetime Achievement Award today at #EHA2026. So utterly well-earned! May we all strive for such brilliance, compassion, and humbleness while we continue to navigate our own careers. #HemaSphereProud

Learn more about serving as a scientific journal peer reviewer. Equally, gain intel on how to make your own manuscripts shine their brightest for peer reviewers. This is a fun one - all are welcome! 📍Friday, 12 June, 13:45 - 15:15 🏠Stockholm convention center, room T3 🎤Jan Cools + Juerg Schwaller

Interested in scholarly publishing? Mark your agendas for the #HemaSphere Peer Review Workshop: 📍Fri, 12 June | 13:45 - 15:15 | Room T3 🎤Jan Cools + Juerg Schwaller ℹ️Learn about serving as a scientific journal peer reviewer & gain intel on how your own papers can catch reviewers' eyes.

👋The #HemaSphere team is in Stockholm and looking forward to meeting you. We will be at the EHA booth at various times so please stop by. We are also happy to make appointments to fit your agenda best and discuss your publishing/journal questions. Feel free to reach out. See you soon! #EHA2026

The June issue now open! New papers include new data on iptacopan in #PNH, strategies to improve CD19 #CAR T-cell responses in #DLBCL, #EHA Recommendations on screening for hemoglobinopathies & liquid biopsy for lymphoma diagnosis in TB-endemic settings.  Start here 👉 https://bit.ly/43d4Ks7

Odronextamab induced complete responses in 73.4% of heavily pretreated relapsed or refractory follicular lymphoma patients, often by first assessment, with remissions lasting beyond 2 years. Responses were also seen in high-risk disease and low CD20 expression 👉https://bit.ly/4sN50IH

Sickle cell trait is not transfusion neutral. HbAS donor RBCs store poorly, recover less well after transfusion, and produce lower 24 hour hemoglobin increments, supporting trait-aware transfusion strategies in SCD. Read more about it 👉https://bit.ly/4cBmtxz

HemaTopics are HemaSphere pubs focusing on 🔥heme topics.. This week w the latest HemaTopic by Sci Ed E Olayemi, which challenges the idea that #HbSC disease is mild, showing why its serious complications and persistent care gaps demand closer attention 📰https://bit.ly/4tjv2E8

Monocyte-to-myeloma mitochondrial transfer emerges as a CD38/CD31-dependent metabolic support axis boosting OXPHOS, growth, migration & drug resistance. Daratumumab disrupts this, reversing the metabolic advantage & reveals mitochondrial transfer as a vulnerability in #MM👉https://bit.ly/4sHuc3f

Authors of this paper identify PIMT and PCMT1 variation as determinants of red cell storage biology and transfusion response, highlighting a protective rs4816 allele with potential relevance for donor selection and patient outcomes.  Learn more https://bit.ly/4couQOo

New episode: p53 in normal blood formation + MPNs. Dr Charles de Bock talks with Dr Isabelle Plo & Dr Barbara Monte-Mór on TP53 mutations, leukemic transformation, and emerging p53‑targeted therapies. Listen: https://bit.ly/4tq6QQ2 Review: https://bit.ly/4sZbo01

#AML may affect the brain beyond hematopoiesis, with the authors linking disease progression to blood brain barrier disruption, neuroinflammation, and signs of neuronal injury. A compelling finding for clinicians and researchers to explore further. Read more in depth 👉https://bit.ly/4thKuR2

This Perspective shows how hematology care can adapt during war. The authors share lessons from the EHA-ASH joint Workshop Ukraine on resilience, collaboration, and practical ways to support care in crisis. Learn more 👉https://bit.ly/4tnSmkt #EHA2025

This recently published paper highlights how clearer diagnostic criteria and a stronger understanding of complement driven biology are reshaping care for TA-TMA. The authors outline why earlier recognition and targeted therapy may improve outcomes. Learn more👉 https://bit.ly/499L2AP

In this paper, the authors report that severe neurotoxicity after pediatric #CART therapy is most linked to high preinfusion marrow disease burden & prior transient neurologic events. Low-burden patients still accounted for many cases, underscoring vigilance 👉https://bit.ly/3PWVvZX

New episode: p53 in normal blood formation + MPNs. Dr Charles de Bock talks with Dr Isabelle Plo & Dr Barbara Monte-Mór on TP53 mutations, leukemic transformation, and emerging p53‑targeted therapies. Listen: https://bit.ly/4tq6QQ2 Review: https://bit.ly/4sZbo01

Casein kinase 1δ/ε inhibition exerts multi-hit activity in #CLL: enforces intrinsic S/G2 cell-cycle arrest & disrupts lymph microenvironmental survival cues by blocking CD40L-driven NFκB signaling, limiting proliferation w/ reduced efficacy in TP53-defective disease ➡️https://bit.ly/4c5opiQ

Total absence of granulopoiesis at childhood ALL diagnosis marks a subgroup, enriched in favorable risk B-ALL, with very high early bloodstream infection risk during induction, & authors suggest this finding could guide safer antibiotic strategies. Learn more 👉https://bit.ly/4lqATVB

Hetrombopag acts as a potent oral iron chelator. Longitudinal data in severe aplastic anemia & transfusion iron overload models show reductions in systemic iron burden, linked to ferroptosis inhibition via reduced lipid peroxidation & iron toxicity👉 https://bit.ly/4cAwjSd

Pan-European mapping shows EU-approved commercial CAR-T access remains uneven & often absent: 25% of countries had no product available & time to access ranged from 0 to 53 months. Cost, reimbursement delays & capacity gaps drive inequity. 👉 https://bit.ly/471Qfdd

This paper shows that in KMT2A-rearranged #B-ALL, early treatment response varies strongly w/ age, leukemia developmental state & fusion partner, authors linking these features to MRD clearance & drug sensitivity, showing venetoclax as a potential option in immature cases👉https://bit.ly/4qFGFmZ

In this recent paper finds CALR-mutated ET, CALR variant allele frequency & high molecular risk mutations predict cytoreductive response & key outcomes better than CALR mutation type. Highlighting VAF as a marker of lower response & higher thrombosis & MF risk. 👉https://bit.ly/4rRMRcf

This 🔥HemaTopics by Sci Ed L Merz highlights a growing gap btwn research criteria & bedside care in obs antiphospholipid syndrome, arguing that pts who meet the 2006 criteria may still warrant aspirin ➕ anticoagulation, even if they no longer meet the 2023 criteria 👉https://bit.ly/4lHLGKW

After showing ruxolitinib’s promise in immune aplastic anemia, authors explore selective JAK inhibition to refine therapy & reduce toxicity. #HemaSphere. #Hematology. #Jakinhibitors Read more about it here👉https://bit.ly/4blYqmX

Don't have plans? A powerful new theatre piece, created with our Scientific Ed S. Hibbs, brings to life the realities of sickle cell crises and reimagines what good care could be. Showing at BSH ASM + across London. Info: www.crescentcell.com  #BSH2026

This paper in the March issue shows PBMC multi-omics can distinguish #SCD, PH & #SCD–PH using clear immune-metabolic signatures, including iron loading, arginine disruption & oxidative stress; highlighting PBMCs as an accessible route to stratification & biomarkers 👉https://bit.ly/4bxxO2s

This paper shows how NCOA2 helps hematopoietic stem cells recover after irradiation by reducing mitochondrial stress and restoring quiescence. The authors reveal a FOXO3a‑dependent mitophagy pathway that preserves long‑term stem cell function. Read more 👉https://bit.ly/4b9djrr

This paper questions severity‑based treatment for #iMCD‑IPL. The authors show that patients labelled “severe” have outcomes similar to non‑severe disease, with no clear benefit from treatment intensification, supporting subtype‑informed management. Learn more here 👉https://bit.ly/4ruiSYH

Clonal hematopoiesis in #CLL affects survival, treatment toxicity, and transformation risk. The authors link specific mutations to poorer outcomes and immune changes, highlighting why CH matters in clinical decision‑making. Read more https://bit.ly/4rv9hRd

Authors in this paper show that bone marrow plasma cell counts add little once serum immunofixation is negative,  demonstrating that mass spectrometry better detects residual disease & prognosis, offering a more accurate, noninvasive way to assess response 👉https://bit.ly/4rYzoQb

In this recent paper, authors present a simple flow cytometry prognostic score for myelodysplastic neoplasms. It predicts overall survival and improves risk stratification beyond current scores, supporting earlier, more precise clinical decisions. Learn more.👉https://bit.ly/3ZPiwiM

🚨 In this extended episode host Sci Ed Charles de Bock discusses #SCD w/ co-authors, covering both expert & lived-patient perspectives This episode is on our website & all major podcast platforms. Listen & enjoy casual, insightful discussions about #hematology research https://bit.ly/4nIhH68